The FDA withdrew its final rule on laboratory-developed tests (LDTs), reverting to prior regulatory frameworks that limit agency oversight of these in vitro diagnostics. This decision impacts clinical laboratories and diagnostic developers by preserving existing autonomy over LDTs. The move reflects ongoing debates surrounding regulatory balance between innovation, patient safety, and market access in diagnostic testing.